ZyVersa Therapeutics, a clinical-stage biopharmaceutical company, has merged with Larkspur Health Acquisition Corp., a blank-check special purpose acquisition company.

The deal provides ZyVersa access to the public equity market and escalates the development of ZyVersa’s products.

“We are delighted to partner with Larkspur in this business combination. Their management and board have vast experience as investors and operating executives in the biopharmaceutical industry,” stated Stephen C. Glover, CEO of ZyVersa. “This merger and entry into the public markets will enable us to escalate the development of our pipeline drug candidates for targeted patients with renal and inflammatory diseases, who need disease-modifying drugs that are well tolerated and safe.”

The Benchmark Company LLC and Noble Capital Markets are serving as financial advisors to ZyVersa. Lowenstein Sandler LLP is acting as legal advisor to ZyVersa. Alliance Global Partners is serving as financial advisor to Larkspur. Alston & Bird LLP is acting as legal advisor to Larkspur. Manatt, Phelps & Phillips LLP is serving as legal advisor to Alliance.